System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Umut Demirci is an expert in Oncology at Memorial Ankara Hospital (Turkey). As of October 2026, ScienceLeadR ranks Umut Demirci in the top 1% of experts in Turkey for Breast Neoplasms, Breast Diseases and Carcinoma. Umut Demirci has authored 179 publications, the most recent in 2026, and is an investigator in 10 clinical trials, 9 of them ongoing. SLR score: 707 (community average: 125). How the SLR is computed.

LeadR Profile

Umut Demirci Memorial Ankara Hospital Turkey
707 ScienceLeadR Reputation 707

Unlock

Register Login
Network Map

Oncology

Subspecialties: Pharmacy - Pulmonology - Public Health

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Organizations

Career arc: 2009 - 2026
Source: PubMed

Memorial Ankara Hospital

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 179

Citations

Citations: 1 433 1st author: 22 Last author: 24 Unique author: 0

Main journals

J Clin Oncol 20
Asian Pac J Cancer Prev 17
Ann Oncol 10
J BUON 10
Med Oncol 6

Best Journals

J Clin Oncol 9
Ann Oncol 6
N Engl J Med 4

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Extended follow-up of tarlatamab in patients with small-cell lung cancer after platinum-based chemotherapy in the randomized phase 3 DeLLphi-304 study.
PMID 42933636 — cells, lung, safety, neoplasms, drug therapy, immunotherapy, lung neoplasms, small cell lung carcinoma, therapeutics, chemotherapy		Ann Oncol Top journal20260
Overall survival from the phase III postMONARCH trial of abemaciclib plus fulvestrant versus placebo plus fulvestrant for HR+, HER2- advanced breast cancer following progression on a prior CDK4/6 inhibitor plus endocrine therapy.
PMID 42926108 — fulvestrant, breast neoplasms, neoplasms, disease progression, breast, therapeutics		Ann Oncol Top journal20260
Adding immunotherapy to chemotherapy may improve survival after SCLC transformation in EGFR-mutant NSCLC: a multicenter real-world study.
PMID 42664544 — cells, lung, neoplasms, carcinoma, non-small-cell lung, biopsy, drug therapy, immunotherapy, lung neoplasms, diagnosis, therapeutics, chemotherapy		Lung Cancer20260
Patient-reported outcomes with tarlatamab in extensive-stage small cell lung cancer after platinum-based chemotherapy: results from the phase 3 DeLLphi-304 trial.
PMID 42679738 — cells, quality of life, lung, pain, neoplasms, drug therapy, signs and symptoms, lung neoplasms, small cell lung carcinoma, patient reported outcome measures, therapeutics, chemotherapy		Lung Cancer20261
Preimplantation genetic testing (PGT-M) awareness in BRCA-positive individuals in Türkiye: a dual physician-patient survey.
PMID 42414499 — research design, genetic testing, physicians, counseling		Sci Rep20261

Clinical Studies 10

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 1

By phase:

Phase 3 8
N/A 1
Phase 2 1

By status:

Active not recruiting 7
Recruiting 2
Completed 1

By type:

Interventional 9
Observational 1

By Monocentric/Multicentric:

monocentric 0
multicentric2to4 0
multicentric5to9 0
multicentricup10 10

Main Topics

Ongoing Clinical Trials

9 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
TRIMPACT Real World First Line Atezolizumab Use in Stage IV NSCLC With PD L1 50
NCT07279402 — cells, genes, lung, neoplasms, carcinoma, non-small-cell lung, lung neoplasms, small cell lung carcinoma, therapeutics, mutation, carcinoma		N/ARecruiting2025
IMC F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM MEL 301)
NCT06112314 — cells, hla-a antigens, melanoma, solutions, nivolumab, t-lymphocytes, receptors, antigen, t-cell		Phase 3Recruiting2024
Trial of Two Adagrasib Dosing Regimens in NSCLC With KRAS G12C Mutation (KRYSTAL 21)
NCT05853575 — cells, lung, neoplasms, carcinoma, non-small-cell lung, lung neoplasms, neoplasm metastasis, small cell lung carcinoma, mutation, carcinoma		Phase 2Active not recruiting2024
Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung Cancer
NCT05740566 — cells, lung, neoplasms, drug therapy, lung neoplasms, small cell lung carcinoma, topotecan, chemotherapy, carcinoma		Phase 3Active not recruiting2023
A Study to Learn About a New Medicine Called Vepdegestrant (ARV 471 PF 07850327) in People Who Have Advanced Metastatic Breast Cancer
NCT05654623 — fulvestrant, estrogens, breast neoplasms, receptors, estrogen, neoplasms, anti-retroviral agents, hormones, breast, therapeutics		Phase 3Active not recruiting2023

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS